407 related articles for article (PubMed ID: 22716970)
21. Novel integrase inhibitors for HIV.
Prada N; Markowitz M
Expert Opin Investig Drugs; 2010 Sep; 19(9):1087-98. PubMed ID: 20707594
[TBL] [Abstract][Full Text] [Related]
22. Discordant predictions of residual activity could impact dolutegravir prescription upon raltegravir failure.
Theys K; Abecasis A; Libin P; Gomes PT; Cabanas J; Camacho RJ; Van Laethem K
J Clin Virol; 2015 Sep; 70():120-127. PubMed ID: 26305833
[TBL] [Abstract][Full Text] [Related]
23. Development of a phenotypic susceptibility assay for HIV-1 integrase inhibitors.
Heger E; Theis AA; Remmel K; Walter H; Pironti A; Knops E; Di Cristanziano V; Jensen B; Esser S; Kaiser R; Lübke N
J Virol Methods; 2016 Dec; 238():29-37. PubMed ID: 27737783
[TBL] [Abstract][Full Text] [Related]
24. Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort.
Modica S; Rossetti B; Lombardi F; Lagi F; Maffeo M; D'Autilia R; Pecorari M; Vicenti I; Bruzzone B; Magnani G; Paolucci S; Francisci D; Penco G; Sacchini D; Zazzi M; De Luca A; Di Biagio A
HIV Med; 2019 Feb; 20(2):137-146. PubMed ID: 30461149
[TBL] [Abstract][Full Text] [Related]
25. New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors.
Malet I; Gimferrer Arriaga L; Artese A; Costa G; Parrotta L; Alcaro S; Delelis O; Tmeizeh A; Katlama C; Valantin MA; Ceccherini-Silberstein F; Calvez V; Marcelin AG
J Antimicrob Chemother; 2014 Aug; 69(8):2118-22. PubMed ID: 24710029
[TBL] [Abstract][Full Text] [Related]
26. Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors.
Oliveira M; Mesplède T; Quashie PK; Moïsi D; Wainberg MA
AIDS; 2014 Mar; 28(6):813-9. PubMed ID: 24463394
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors.
Scutari R; Alteri C; Vicenti I; Di Carlo D; Zuccaro V; Incardona F; Borghi V; Bezenchek A; Andreoni M; Antinori A; Perno CF; Cascio A; De Luca A; Zazzi M; Santoro MM;
J Glob Antimicrob Resist; 2020 Mar; 20():163-169. PubMed ID: 31330378
[TBL] [Abstract][Full Text] [Related]
28. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance.
Lataillade M; Chiarella J; Kozal MJ
Antivir Ther; 2007; 12(4):563-70. PubMed ID: 17668566
[TBL] [Abstract][Full Text] [Related]
29. Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response.
Requena S; Treviño A; Cabezas T; Garcia-Delgado R; Amengual MJ; Lozano AB; Peñaranda M; Fernández JM; Soriano V; de Mendoza C;
J Antimicrob Chemother; 2017 Jul; 72(7):2083-2088. PubMed ID: 28369593
[TBL] [Abstract][Full Text] [Related]
30. Early emergence of raltegravir resistance mutations in patients receiving HAART salvage regimens.
Baldanti F; Paolucci S; Gulminetti R; Brandolini M; Barbarini G; Maserati R
J Med Virol; 2010 Jan; 82(1):116-22. PubMed ID: 19950236
[TBL] [Abstract][Full Text] [Related]
31. In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir.
Canducci F; Ceresola ER; Saita D; Castagna A; Gianotti N; Underwood M; Burioni R; Lazzarin A; Clementi M
J Antimicrob Chemother; 2013 Nov; 68(11):2525-32. PubMed ID: 23798668
[TBL] [Abstract][Full Text] [Related]
32. The M184I/V and K65R nucleoside resistance mutations in HIV-1 prevent the emergence of resistance mutations against dolutegravir.
Oliveira M; Ibanescu RI; Pham HT; Brenner B; Mesplède T; Wainberg MA
AIDS; 2016 Sep; 30(15):2267-73. PubMed ID: 27367488
[TBL] [Abstract][Full Text] [Related]
33. The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation.
Delelis O; Malet I; Na L; Tchertanov L; Calvez V; Marcelin AG; Subra F; Deprez E; Mouscadet JF
Nucleic Acids Res; 2009 Mar; 37(4):1193-201. PubMed ID: 19129221
[TBL] [Abstract][Full Text] [Related]
34. Molecular dynamic simulations to investigate the structural impact of known drug resistance mutations on HIV-1C Integrase-Dolutegravir binding.
Chitongo R; Obasa AE; Mikasi SG; Jacobs GB; Cloete R
PLoS One; 2020; 15(5):e0223464. PubMed ID: 32379830
[TBL] [Abstract][Full Text] [Related]
35. In-vitro phenotypic susceptibility of HIV-1 'non-B' integrase inhibitors naive clinical isolates to dolutegravir and raltegravir.
Charpentier C; Bertine M; Visseaux B; Leleu J; Larrouy L; Peytavin G; Mourez T; Collin G; Brun-Vézinet F; Plantier JC; Descamps D
AIDS; 2013 Nov; 27(18):2959-61. PubMed ID: 23942060
[TBL] [Abstract][Full Text] [Related]
36. Dolutegravir, a second-generation integrase inhibitor for the treatment of HIV-1 infection.
Rathbun RC; Lockhart SM; Miller MM; Liedtke MD
Ann Pharmacother; 2014 Mar; 48(3):395-403. PubMed ID: 24259658
[TBL] [Abstract][Full Text] [Related]
37. The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates.
Buzón MJ; Dalmau J; Puertas MC; Puig J; Clotet B; Martinez-Picado J
AIDS; 2010 Jan; 24(1):17-25. PubMed ID: 19770695
[TBL] [Abstract][Full Text] [Related]
38. Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes.
Hightower KE; Wang R; Deanda F; Johns BA; Weaver K; Shen Y; Tomberlin GH; Carter HL; Broderick T; Sigethy S; Seki T; Kobayashi M; Underwood MR
Antimicrob Agents Chemother; 2011 Oct; 55(10):4552-9. PubMed ID: 21807982
[TBL] [Abstract][Full Text] [Related]
39. Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen.
Roquebert B; Blum L; Collin G; Damond F; Peytavin G; Leleu J; Matheron S; Chêne G; Brun-Vézinet F; Descamps D;
AIDS; 2008 Oct; 22(15):2045-6. PubMed ID: 18784469
[No Abstract] [Full Text] [Related]
40. Absence of HIV-1 Drug Resistance Mutations Supports the Use of Dolutegravir in Uganda.
Ndashimye E; Avino M; Kyeyune F; Nankya I; Gibson RM; Nabulime E; Poon AFY; Kityo C; Mugyenyi P; Quiñones-Mateu ME; Arts EJ
AIDS Res Hum Retroviruses; 2018 May; 34(5):404-414. PubMed ID: 29353487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
